Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets
- PMID: 16403733
- DOI: 10.1096/fj.05-5128fje
Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets
Abstract
Xanthohumol (XN), the principal flavonoid of the hop plant (Humulus lupulus L.) and a constituent of beer, has been suggested to have potential cancer chemopreventive activities. We have observed that most cancer chemopreventive agents show antiangiogenic properties in vitro and in vivo, a concept we termed "angioprevention." Here we show for the first time that XN can inhibit growth of a vascular tumor in vivo. Histopathology and in vivo angiogenesis assays indicated that tumor angiogenesis inhibition was involved. Further, we show the mechanisms for its inhibition of angiogenesis in vivo and related endothelial cell activities in vitro. XN repressed both the NF-kappaB and Akt pathways in endothelial cells, indicating that components of these pathways are major targets in the molecular mechanism of XN. Moreover, using in vitro analyses, we show that XN interferes with several points in the angiogenic process, including inhibition of endothelial cell invasion and migration, growth, and formation of a network of tubular-like structures. Our results suggest that XN can be added to the expanding list of antiangiogenic chemopreventive drugs whose potential in cancer prevention and therapy should be evaluated.
Similar articles
-
Pharmacological profile of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus).Molecules. 2015 Jan 7;20(1):754-79. doi: 10.3390/molecules20010754. Molecules. 2015. PMID: 25574819 Free PMC article. Review.
-
Hop derived flavonoid xanthohumol inhibits endothelial cell functions via AMPK activation.Oncotarget. 2016 Sep 13;7(37):59917-59931. doi: 10.18632/oncotarget.10990. Oncotarget. 2016. PMID: 27494895 Free PMC article.
-
AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies.Cancer. 2007 Nov 1;110(9):2007-11. doi: 10.1002/cncr.23017. Cancer. 2007. PMID: 17823911
-
Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy.Oncogene. 2005 Feb 10;24(7):1188-202. doi: 10.1038/sj.onc.1208276. Oncogene. 2005. PMID: 15558015
-
Broad spectrum anti-infective potential of xanthohumol from hop (Humulus lupulus L.) in comparison with activities of other hop constituents and xanthohumol metabolites.Mol Nutr Food Res. 2005 Sep;49(9):827-31. doi: 10.1002/mnfr.200500091. Mol Nutr Food Res. 2005. PMID: 16092071 Review.
Cited by
-
Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma.Sarcoma. 2009;2009:794901. doi: 10.1155/2009/794901. Epub 2009 Mar 24. Sarcoma. 2009. PMID: 19325926 Free PMC article.
-
Xanthohumol Impairs the PMA-Driven Invasive Behaviour of Lung Cancer Cell Line A549 and Exerts Anti-EMT Action.Cells. 2021 Jun 12;10(6):1484. doi: 10.3390/cells10061484. Cells. 2021. PMID: 34204745 Free PMC article.
-
Pharmacological profile of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus).Molecules. 2015 Jan 7;20(1):754-79. doi: 10.3390/molecules20010754. Molecules. 2015. PMID: 25574819 Free PMC article. Review.
-
Stepwise Targeted Matching Strategy for Comprehensive Profiling of Xanthohumol Metabolites In Vivo and In Vitro Using UHPLC-Q-Exactive Orbitrap Mass Spectrometer.Molecules. 2023 Jul 2;28(13):5168. doi: 10.3390/molecules28135168. Molecules. 2023. PMID: 37446828 Free PMC article.
-
Evidence for the Effects of Xanthohumol in Disrupting Angiogenic, but not Stable Vessels.Int J Biomed Sci. 2007 Dec;3(4):279-86. Int J Biomed Sci. 2007. PMID: 23675054 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources